RE: Musings : Asthma /JAK's and TYK2 Inhalers18 Aug 2021 15:14
NGX has developed a new form of the drug tranilast, as an inhaled formula with potential in fibrosis, including IPF.
Tranilast inhibits pulmonary fibrosis by suppressing TGFß/SMAD2-mediated extra-cellular matrix (ECM) protein production, a major therapeutic target in IPF, presenting it as a promising and novel anti-fibrotic agent.